$ALAB

Dyckerhoff Stefan A sold $2.5M of ALAB (indirect holdings)

Dyckerhoff Stefan A sold 8,994 indirectly-held shares of Astera Labs, Inc. (ALAB) at an average of $274.96 ($273.64–$276.75, $2.47M total) across 8 trades on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dyckerhoff Stefan A
Published Sep 3, 2026, 11:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 11:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The transaction provides fresh data on insider holdings but is unlikely to move the stock significantly.

02

Market read

Insider sale of modest size; traders may note but not act aggressively.

03

What to watch

The director still holds over 3,000 shares, indicating continued belief in the company.

Relevance 5/10Novelty 5/10Timing: post‑market 2026‑09‑02

Background

Form 4 filings disclose insider transactions; a director's sale via a pre‑arranged plan is a standard compliance disclosure.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Director Stefan A. Dyckerhoff sold 8,994 shares of Astera Labs for $2.47M via a 10b5‑1 plan, reducing his holding to 3,309 shares.

Expected impact

Potential short‑term downward pressure, likely limited to a few basis points.

Evidence & confidence

A $2.5M sale by a director is a routine 10b5‑1 execution; markets typically view such trades as low‑impact unless the insider is a major shareholder.

Market effects

Minor signal for the semiconductor equipment sector; no broader industry impact.

U.S. market only; no regional ripple effects.

Limited to investors tracking Astera Labs.

Counterpoint

The sale could be purely procedural under a 10b5‑1 plan, not reflecting insider confidence.

Key entities

  • Astera Labs, Inc.

    U.S. listed semiconductor firm (ticker ALAB).

  • Stefan A. Dyckerhoff

    Director of Astera Labs executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALABMed

Astera Labs Stock Jumps 11% as Scorpio Faces a 40% Sales Ramp

Astera Labs (ALAB) shares rose 11% to $313.84 on Friday, driven by strong semiconductor sector performance and positive investor sentiment. The company must achieve a 40% sales increase in Q3 to meet guidance, with Scorpio expected to be its largest product family. Revenue grew 104% year-over-year in Q2, but high customer concentration and stock compensation costs pose risks.

$ALABHighAI 8/10

Why is Astera Labs stock surging today?

Astera Labs (ALAB) stock surged 12.8% after reporting Q2 2026 revenue of $392.4M, up 104% YoY, and Q3 guidance of $540M-$560M. Analysts raised price targets, with Citi at $430 and Roth Capital at $450. The company's AI products gained traction, and an upcoming conference may attract institutional interest.

$ALABMed

3 Millionaire-Maker Artificial Intelligence (AI) Stocks to Buy Now

Astera Labs (ALAB) reported Q1 2026 revenue of $308.4M, up 93% YoY, with 76.3% gross margin. Credo Technology (CRDO) saw Q2 2026 revenue of $268M, up 272% YoY, and guided for over 200% FY growth. Vertiv (VRT) reported a $15B backlog with a 2.9 book-to-bill ratio in Q4 2025, expanding liquid cooling capacity. All three companies are involved in AI infrastructure.